

# Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands

著者	Yano Seiji, Takeuchi Shinji, Nakagawa Takayuki, Yamada Tadaaki
journal or publication title	Cancer Science
volume	103
number	7
page range	1189-1194
year	2012-07-01
URL	<a href="http://hdl.handle.net/2297/31370">http://hdl.handle.net/2297/31370</a>

doi: 10.1111/j.1349-7006.2012.02279.x

**Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of HGF and EGFR ligands.**

Seiji Yano<sup>1,3</sup>, Shinji Takeuchi<sup>1</sup>, Takayuki Nakagawa<sup>1,2</sup>, Tadaaki Yamada<sup>1</sup>.

<sup>1</sup>Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, and

<sup>2</sup>Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.

Key words: HGF, EGFR ligands, *EGFR* mutation, *EML4-ALK*, gefitinib, erlotinib, crizotinib

<sup>3</sup>To whom correspondence should be addressed.

E-mail:syano@staff.kanazawa-u.ac.jp

TEL 076-265-2794 / FAX 076-234-4524

Word count: 5147

## **Abstract**

Recent advances in molecular biology have led to the identification of new molecular targets, such as epidermal growth factor receptor (*EGFR*) mutations and echinoderm microtubule-associated protein-like 4 (*EML4*) - anaplastic lymphoma kinase (*ALK*) fusion gene, in lung cancer. Dramatic response has been achieved with *EGFR* inhibitors (gefitinib and erlotinib) and an *ALK* inhibitor (crizotinib) in lung cancer expressing corresponding targets. However, cancer cells acquire resistance to these drugs and cause recurrence. Known major mechanisms for resistance to molecular targeted drugs include gatekeeper mutations in the target gene and activation of bypass survival signal via receptors other than the target receptors. The latter mechanism can involve receptor gene amplification and ligand-triggered receptor activation as well. For example, hepatocyte growth factor (HGF), the ligand of a tyrosine kinase receptor Met, activates Met and the downstream PI3K/Akt pathway and triggers resistance to *EGFR* inhibitors in *EGFR* mutant lung cancer cells. Moreover, *EGFR* ligands activate *EGFR* and downstream pathways and trigger resistance to crizotinib in *EML4-ALK* lung cancer cells. These observations indicate that signals from oncogenic drivers (*EGFR* signaling in *EGFR*-mutant lung cancer and *ALK* signaling in *EML4-ALK* lung cancer) and ligand-triggered bypass signals (HGF-Met and *EGFR* ligands-*EGFR*, respectively) must be simultaneously blocked to avoid the resistance.

This review focuses specifically on receptor activation by ligand stimulation and discusses novel therapeutic strategies that are under development for overcoming resistance to molecular targeted drugs in lung cancer.

### **Abbreviations**

IFN	interferon
IGF-1R	insulin-like growth factor-1 receptor
IL-1	interleukin-1
PDGF	platelet-derived growth factor
PI3K	phosphatidylinositol 3-kinase
mTOR	mammalian target of rapamycin
TNF	tumor necrosis factor
TGF	transforming growth factor

## **Introduction**

Lung cancer is the leading cause of cancer death worldwide. Several oncogenic drivers, including epidermal growth factor receptor (*EGFR*) mutations (1, 2) and echinoderm microtubule-associated protein-like 4 (*EML4*) - anaplastic lymphoma kinase (*ALK*) fusion gene (3), have been recently discovered in lung cancer. Dramatic results have been achieved with *EGFR* inhibitors (4, 5) and an *ALK* inhibitor (6) in lung cancer expressing corresponding targets, and a paradigm shift in treatment is occurring. However, some patients who have responded to those inhibitors acquire resistance to them within a few years and experience the recurrence of cancer (7, 8). This clinical issue now needs to be resolved.

A gatekeeper mutation occurring at the binding site of a molecular targeted drug is a typical mechanism for development of acquired resistance (9). Another crucial mechanism is bypass signals to prevent apoptosis (10). In addition to receptor gene alterations (e.g. gene mutations and gene amplification) besides target genes, activation of receptors by ligands plays an important role in bypass signaling (11). In recent years, vigorous attempts have been made to overcome resistance through therapies combining drugs that alleviate resistance due to gatekeeper mutations and drugs that block bypass signals. This paper reviews resistance to molecular targeted drugs caused by receptor activation as a result of ligand stimulation. Using lung cancer as an example, this paper describes the molecular mechanisms for that resistance

and therapies to overcome it.

### **Oncogenic drivers of lung cancer**

Alteration in genes such as *KRAS* (12), *EGFR* (1, 2), *EML4-ALK* (3), *DDR2* (13), and *ROS* (14) are known to be oncogenic drivers for lung cancer. Selective inhibitors of *EGFR* gene mutations and the *EML4-ALK* fusion gene have been developed and the clinical efficacy of these drugs has been demonstrated (4-6, 15), resulting in their routine clinical use. *EGFR* gene mutations such as exon 19 deletion and a point mutation in L858R in exon 21 cause activation of EGFR; the two account for 90% or more of the *EGFR* gene mutations overall (16). Lung cancers with such *EGFR*-activating mutations respond to a reversible EGFR-tyrosine kinase inhibitors (TKIs) such as gefitinib or erlotinib at a rate of 70-80% (7). Recent phase III clinical trials revealed that EGFR-TKI therapy to treat lung cancer with *EGFR*-activating mutations resulted in a median survival time (MST) of about 30 months (4, 5). This is clearly a breakthrough in treatment, given that the usual MST for non-small cell lung cancer is 10-14 months (17, 18). *EML4-ALK* is a fusion gene that was first discovered as a factor for development of lung cancer, which are considered typical solid tumors (3). *EML4-ALK* is found in about 5% of cases of pulmonary adenocarcinoma. *EML4-ALK* lung cancer is highly prevalent in patients with pulmonary adenocarcinoma who are never or light smokers and age

50 and under, and rarely found in patients with *EGFR*-activating mutations or *KRAS* mutations (3, 19). Histologically, the cancer often produces an acinar pattern (19). The cancer responds well (60% and more) to crizotinib (6, 8), which has ALK-inhibiting activity, and has a prognosis on par with *EGFR*-mutant lung cancer treated with EGFR-TKI therapy.

Nevertheless, most patients who have lung cancer with *EGFR*-activating mutations and who have undergone EGFR-TKI therapy or who have *EML4-ALK* lung cancer and who have undergone ALK inhibitor therapy acquire resistance after several years and experience recurrence of the cancer. In addition, 20-30% of patients fail to respond to the EGFR-TKI or ALK inhibitor despite having *EGFR* mutations or the *EML4-ALK* fusion gene. In other words, patients with initial resistance pose a clinical problem.

### **Major mechanisms for resistance to molecular targeted drugs in lung cancer**

Known mechanisms for resistance to targeted drugs include gene mutations produced at the drug's binding site (gatekeeper mutations, such as *EGFR*-T790M and *ALK*-L1196M) (20-22), activation of bypass signals via receptors other than the target receptors (Met activation in EGFR-TKI resistance) (11, 23), target gene amplification (*ALK* amplification in ALK-TKI resistance) (24), and activation downstream of the target (25-27). The activation of receptors other than the target receptors can involve amplification of receptor genes or ligand stimulation.

This paper focuses specifically on receptor activation by ligand stimulation and reviews recent findings.

### **Mechanisms of resistance to EGFR-TKIs**

*EGFR*-mutant lung cancer is extremely sensitive to gefitinib and erlotinib. **Table 1** shows the major resistance mechanisms to EGFR-TKIs. HGF (28, 29), a ligand of the tyrosine kinase receptor Met, has been found to bind to Met and activate the PI3K/Akt pathway, thereby inducing EGFR-TKI resistance (11) (**Figure 1**). HGF is a factor produced by lung cancer cells (30, 31) as well as by stromal cells (microenvironments) such as fibroblasts (32). HGF is involved in the carcinogenesis (33), invasion/motility (34), epithelial-to-mesenchymal transition (EMT) (35), angiogenesis (36), and metastasis (37) in lung cancer, and therefore associates with poor prognosis of the patients (38, 39) (**Figure 2**). Moreover, regardless of whether it is produced by cancer cells or fibroblasts, HGF induces EGFR-TKI resistance (40). None of other receptor ligands, including EGF, TGF- $\alpha$ , and IGF-1, could induce EGFR-TKI-resistance in *EGFR* mutant lung cancer cells (11, 42), indicating that EGFR-TKI resistance is induced selectively by HGF.

To determine the clinical significance of resistance triggered by HGF, a joint study of Japanese patients with *EGFR*-mutant lung cancer was conducted at 12 facilities (41). The

study analyzed the prevalence of HGF, T790M, and *Met* amplification in tissues from patients with EGFR-TKI resistance (**Figure 3**). Of 23 tumors with acquired resistance, 14 had high levels of HGF expression (61%), 12 had T790M (52%), and 2 had *Met* amplification (9%). High levels of HGF expression were detected most often. Of 45 tumors that did not respond to EGFR-TKI despite having *EGFR* mutations, 13 had high levels of HGF expression (29%), 0 had T790M (0%), and 4 had *Met* amplification (4%). High levels of HGF expression were again detected most often. Results thus suggested that HGF induces acquired and intrinsic resistance to EGFR-TKI and is the most prevalent factor for resistance, at least in Japanese patients with *EGFR*-mutant lung cancer. Therefore, HGF is an important therapeutic target for overcoming EGFR-TKI resistance in *EGFR* mutant lung cancer.

In all of the patients with acquired resistance, HGF originated from cancer cells. Interestingly, 2 of 13 patients with intrinsic resistance had high levels of HGF (15%) expressed by stromal cells rather than cancer cells. Expression of HGF is enhanced by inflammatory cytokines (IL-1, TNF, and IFN) and suppressed by TGF- $\beta$  (29). However, mechanisms for the enhanced expression of HGF by cancer-associated fibroblasts (CAF) or lung cancer cells as leads to EGFR-TKI resistance have yet to be clarified.

**Relationships between resistance factors themselves.** The aforementioned analysis found that no tumors expressed both T790M and *Met* amplification at the same time. This

corroborates previous results indicating that T790M and *Met* amplification are mutually exclusive (26, 42, 43). An interesting finding is that 6 of 12 tumors expressing T790M were found to also have high levels of HGF expression while 1 of 2 tumors with *Met* amplification also had high levels of HGF expression (41). Thus, HGF is often joined by other factors for resistance, such as T790M and *Met* amplification. The biological significance of this coexistence is described below.

**HGF and *Met* amplification:** Although Turke et al. only noted the phenomenon in the HCC827 cell line, they reported that small numbers of cancer cells with *Met* amplification (0.14%) may already be present (42). In the presence of EGFR-TKI, HGF promotes the selection of cells with *Met* amplification and encourages the emergence of resistance through *Met* amplification. Similarly, examination of clinical specimens from specific patients yielded results indicating the phenomenon whereby HGF accelerated *Met* amplification by expanding pre-existing *Met*-amplified clones.

**HGF and T790M:** Onizuka et al. analyzed tissues from 10 patients with *EGFR*-mutant lung cancer who developed acquired resistance to gefitinib (44). They detected T790M in 7 patients, and they reported that HGF was overly expressed in 5 of 6 patients that were available for analysis. In 27 patients who developed acquired resistance to gefitinib or erlotinib, Turke et al. detected T790M in 15 (42). Of the 15, 11 (73%) had increased levels of expression,

compared to levels before treatment, or high levels of HGF expression. Thus, HGF often co-exists with T790M.

Irreversible EGFR-TKIs that form a covalent bond with EGFR were expected to alleviate resistance due to a secondary *EGFR* mutation, the T790M mutation, and its clinical development is underway. However, irreversible EGFR-TKIs have not performed as well as expected in numerous clinical trials conducted here in Japan and abroad (45). The current authors found that HGF induced resistance to reversible EGFR-TKIs as well as to irreversible EGFR-TKIs (46, 47). T790M and HGF are often both present in tumors that have developed acquired resistance to gefitinib and erlotinib, suggesting that high levels of HGF expression in a tumor may be a reason why irreversible EGFR-TKIs have not been effective in clinical trials. Presumably, a combination of an HGF inhibitor and irreversible EGFR-TKI would be of clinical benefit in treating tumors with high levels of HGF expression.

**Involvement of other receptor ligands.** In squamous cell carcinoma (carcinomas of the head and neck and cervical carcinoma) models with cancer harboring wild-type EGFR, EGFR-TKI resistance due to activation of IGF-1R has been reported in preclinical models (48). Acquired resistance due to activation of IGF-1R has not yet been demonstrated in *EGFR*-mutant lung cancer.

Some lung cancer patients who respond well to treatment with EGFR-TKIs, and who later

experience therapy failure, demonstrate a second response to EGFR-TKI re-treatment after a “drug holiday” (49). Recent study showed that activation of IGF-1R may be involved in a reversible “drug-tolerant” state (50), though this has yet been proven in studies with clinical specimens.

### **Mechanisms of resistance to anti-EGFR antibody**

Cetuximab, a chimeric anti-EGFR antibody, had a statistically significant survival benefit when used together with anticancer agents to treat advanced non-small cell lung carcinoma (FLEX trial) (51). Subsequent biomarker analysis revealed that cetuximab was more efficacious in patients with high levels of EGFR expression than in those with low levels of EGFR expression (52). Elucidation of the molecular mechanisms of cetuximab resistance in patients with high levels of EGFR expression should thus help to sustain the benefits of treatment.

Yamada et al. examined mechanisms for cetuximab resistance using lung cancer cell lines expressing high levels of wild-type *EGFR* or mutant *EGFR* (53). Both H292 (wild-type *EGFR*) and Ma-1 (*EGFR*-mutant; exon 19 deletion) cell lines were sensitive to cetuximab, but HGF induced cetuximab resistance by activating PI3K/Akt pathway (**Figure 4**). In a xenograft model in SCID mice, H292 tumors inoculated with fibroblasts producing large amounts of HGF were resistant to cetuximab. CAFs may express high levels of HGF depending on the patient

(40). These observations suggest that in clinical settings there are some patients in whom CAFs express high levels of HGF and induce cetuximab resistance. This finding needs to be verified using clinical specimens.

### **Mechanisms of resistance to ALK-TKIs**

Crizotinib, an ALK-TKI, responds well to *EML4-ALK* lung cancer (60% or more) and has therapeutic efficacy comparable to that of EGFR-TKI in treating *EGFR*-mutant lung cancer. However, almost every patient who responds well to crizotinib will, without exception, experience recurrence due to acquired resistance (12). The mechanisms for acquired resistance include gatekeeper L1196M mutations (22), *ALK* gene amplification (24), and other *ALK* gene mutations (L1152R, C1156Y, F1174L)(54-57).

With regard to resistance due to ligands, EGFR ligands (EGF, amphiregulin, HB-EGF, and TGF- $\alpha$ ) are reported to induce crizotinib resistance. Sasaki et al. reported that cells derived from pleural effusions of patients with *EML4-ALK* lung cancer who developed acquired resistance to crizotinib displayed the gatekeeper L1196M mutation and high levels of expression of EGFR ligands (EGF and amphiregulin) (55). This suggests the existence of a mechanism of resistance due to activation of an EGFR pathway in an autocrine manner. We reported that exogenously added EGFR ligands activated EGFR pathway and induced resistance to crizotinib

in a paracrine manner (58) (**Figure 4**). Crizotinib has Met-inhibiting action, so HGF did not induce crizotinib resistance. Other receptor ligands, such as IGF-1 and PDGFs, also failed to induce resistance. These observations indicate that when the signal of EML4-ALK, an oncogenic driver, is blocked in *EML4-ALK* lung cancer cells, a bypass signal from another receptor will be activated, leading to resistance.

Preclinical studies have indicated that selective ALK inhibitors (TAE684 and CH5424802) are effective in alleviating gatekeeper mutations and *ALK* gene amplification that induce acquired resistance to crizotinib (56, 59). This should lead to better clinical performance by selective ALK inhibitors, and clinical trials of selective ALK inhibitors are underway. However, resistance is anticipated to occur with selective ALK inhibitors as well, and elucidation of the mechanisms by which it occurs is crucial. Yamada et al. found that both HGF and EGFR ligands induce resistance to the selective ALK inhibitor TAE684. This finding indicates that a selective ALK inhibitor produces greater effect against resistance caused by gatekeeper mutation and amplification in *ALK* than does crizotinib, but it also suggests that resistance due to bypass signaling may occur more readily than would occur with crizotinib. Results of clinical trials should indicate whether a selective ALK inhibitor or multikinase inhibitor like crizotinib is more effective at treating *EML4-ALK* lung cancer.

### **Treatments for resistance due to ligand stimulation**

Signals from oncogenic drivers (EGFR signaling in *EGFR*-mutant lung cancer and ALK signaling in *EML4-ALK* lung cancer) and bypass signals that trigger resistance (HGF-Met and EGFR ligands-EGFR) must be simultaneously blocked to avoid resistance caused by bypass signaling as a result of ligand stimulation.

HGF-Met can be inhibited by Met-TKI, HGF-neutralizing antibody (11, 40, 60), or inhibitors of HGF-Met binding such as anti-Met monoclonal antibody MetMAb (61) and natural antagonist NK4 (40). Inhibitors of downstream molecules, such as PI3K and mTOR, can be also used (62). The current authors have indicated in *in vitro* and *in vivo* models that resistance due to HGF can be alleviated by combined use of EGFR-TKI (gefitinib or erlotinib) and such an inhibitor (40, 42, 46, 47, 60, 62) (**Figure 5**). EGFR-TKIs and anti-EGFR antibody can be used to inhibit EGFR ligands and EGFR (both are used clinically), and resistance to ALK inhibitors can be alleviated through combined use of those EGFR inhibitors.

### **Conclusion**

Mechanisms for resistance to molecularly targeted drugs have gradually been clarified, and strategies to treat that resistance have been indicated. In lung cancer, Met and EGFR pathways are important for transduction of a bypassing signal to survive, but their receptors also play an

important role in hemostasis *in vivo* (29). Thus, the efficacy and safety of therapy by blocking these pathways for long periods must be carefully verified. In many instances, an individual may have several resistant tumor and multiple mechanisms of resistance may be at work. Thus, optimal treatment for each patient requires accurate diagnosis of the mechanism by which the individual patient developed resistance. In such instances, a second biopsy is recommended (26), but in the event of multiple lesions all of their origins would have to be biopsied, a feat that would be rather difficult. A highly reliable, minimally invasive diagnostic technique needs to be developed to achieve that goal.

### **Acknowledgements**

This work was supported by Grants-in-Aid for Cancer Research (Yano, 21390256), Scientific Research on Innovative Areas "Integrative Research on Cancer Microenvironment Network" (S. Yano, 22112010A01) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and Project for Development of Innovative Research on Cancer Therapeutics (P-Direct).

### **Disclosure Statement**

Seiji Yano received honoraria from Chugai Pharmaceutical Co., Ltd. and AstraZeneca. Seiji

Yano received research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd. and Eisai Co., Ltd. Takayuki Nakagawa is an employ of Eisai Co., Ltd.

## References

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2004;350:2129-39.
2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science.* 2004;304:1497-500.
3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561-6.
4. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121-8.
5. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for

- non-small-cell lung cancer with mutated EGFR. *N Engl J Med*. 2010;362:2380-8.
6. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693-703.
  7. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *J Clin Oncol* 2010;28:357–360.
  8. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol*. 2011;12:1004-12.
  9. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. *Nat Rev Cancer*. 2010;10:760-74.
  10. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. *Clin Cancer Res*. 2008;14:2895-9.
  11. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations. *Cancer Res* 2008;68:9479-87.

12. McCoy MS, Toole JJ, Cunningham JM, Chang EH, Lowy DR, Weinberg RA. Characterization of a human colon/lung carcinoma oncogene. *Nature*. 1983;302:79-81.
13. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR kinase gene identify a novel therapeutic target in squamous cell lung cancer. *Cancer Discov* 2011;1:78-89.
14. Bergethon K, Shaw AT, Ignatius Ou SH, et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. *J Clin Oncol*. 2012 Jan 3. [Epub ahead of print]
15. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) *J Clin Oncol*. 2003;21:2237-46 .
16. Herbst RS, Heymach JV, Lippman SM. Lung cancer. *N Engl J Med*. 2008;359:1367-80.
17. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med*. 2002; 346:92-8.
18. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol*. 2007;18:317-23.

19. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. *Mod Pathol.* 2009;22:508-15.
20. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2005;352:786-92.
21. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med.* 2005;2:e73.
22. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med* 2010;363:1734-9.
23. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science.* 2007;316:1039-43.
24. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proc Natl Acad Sci U S A* 2011;108:7535-40.
25. Yamamoto C, Basaki Y, Kawahara A, et al. Loss of PTEN expression by blocking

- nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. *Cancer Res.* 2010;70:8715-25.
26. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011;3:75ra26.
  27. Faber A, Corcoran RB, Ebi H, et al. BIM expression in treatment naïve cancers predicts responsiveness to kinase inhibitors. *Cancer Discov.* 2011;1:352-365.
  28. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. *Nature.* 1989;342:440-3.
  29. Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. *J Gastroenterol Hepatol.* 2011 Jan;26 Suppl 1:188-202.
  30. Harvey, P. Warn A, Newman P, Perry LJ, Ball RY, Warn RM.. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. *J Pathol* 1996;180,389-94.
  31. Olivero, M. Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. *Br J Cancer*

1996;74:1862-8.

32. Tokunou M, Niki T, Eguchi K, et al. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. *Am J Pathol.* 2001;158:1451-63.
33. Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, Siegfried JM. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. *Carcinogenesis.* 2006;27:1547-55.
34. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y, Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. *Cancer Res.* 1997;57:3305-13.
35. Grotegut S, von Schweinitz D, Christofori G, Lehembre F. Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. *EMBO J.* 2006;25:3534-45.
36. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. *Cancer Res.* 2000;60:6737-43.

37. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. *Proc Natl Acad Sci U S A*. 1994;91:4731-5.
38. Ichimura, E., Maeshima, A., Nakajima, T. & Nakamura, T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. *Jpn J Cancer Res* 1996;87,1063-9.
39. Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, Landreneau RJ. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. *Cancer Res*. 1997;57:433-9.
40. Wang W, Li Q, Yamada T, et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. *Clin Cancer Res* 2009,15;6630-8.
41. Yano S, Yamada T, Takeuchi S, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. *J Thorac Oncol* 2011;6:2011-7.
42. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. *Cancer Cell*. 2010;17:77-88.

43. Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. *Clin Cancer Res.* 2010;16:5489-98.
44. Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. *Lung Cancer.* 2010;68:198-203.
45. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. *Lancet Oncol.* 2012;13:e23-31.
46. Yamada T, Matsumoto K, Wang W, et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. *Clin Cancer Res* 2010;16:174-83.
47. Wang W, Li Q, Takeuchi S, et al. E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. *Clin Cancer Res*, in press.
48. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. *Clin Invest.*

2008;118:2609-19.

49. Yano S, Nakataki E, Ohtsuka S, et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. *Oncol Res.* 2005;15:107-11.
50. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell.* 2010;141:69-80.
51. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. *Lancet.* 2009;373:1525-31.
52. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. *Lancet Oncol.* 2012;13:33-42.
53. Yamada T, Takeuchi S, Kita K, et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. *J Thorac Oncol* 2012;7:272-80.

54. Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. *Cancer Res* 2010;70:10038-43.
55. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res* 2011;71:6051-60.
56. Heuckmann JM, Hölzel M, Sos ML, et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. *Clin Cancer Res*. 2011;17:7394-401.
57. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. *Sci Transl Med*. 2012 Jan 25. [Epub ahead of print]
58. Yamada T, Takeuchi S, Nakade J, et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. in revision.
59. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. *Cancer Cell* 2011;19:679-90.
60. Okamoto W, Okamoto I, Tanaka K, et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF

in non-small cell lung cancer with an EGFR mutation. *Mol Cancer Ther* 2010;9:2785-92.

61. Jin H, Yang R, Zheng Z, et al. MetMAB, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. *Cancer Res* 2008;68:4360-8.
62. Donev IS, Wang W, Yamada T, et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. *Clin Cancer Res* 2011 17;2260-9.

### Figure legends

**Figure 1 Resistance signals to EGFR-TKIs in *EGFR* mutant lung cancer cells.** **A.** Mutant EGFR associates with ErbB3 and transduces survival signal through PI3K/Akt pathway. **B.** EGFR-TKIs, such as gefitinib and erlotinib, bind to tyrosine kinase domain of mutant EGFR and shut off the signal and induce apoptosis. **C.** *EGFR*-T790M gatekeeper mutation results in preventing EGFR-TKIs to bind EGFR, and thereby induces resistance. **D.** Amplified *Met* associates with ErbB3, transactivates the downstream signaling pathway, PI3K-Akt, and thereby

induces resistance. **E.** HGF phosphorylates Met and activates PI3K-Akt pathway, independent of EGFR or ErbB3, and thereby induces resistance. “P” indicates phosphorylation.

**Figure 2 Role of HGF-Met in lung cancer.** HGF is involved in the carcinogenesis, invasion/motility, EMT, angiogenesis, and metastasis, and therefore associates with poor prognosis of lung cancer. Moreover, HGF triggers resistance of *EGFR* mutant lung cancer cells to reversible EGFR-TKIs, irreversible EGFR-TKIs, and mutant EGFR selective TKIs.

**Figure 3 Incidence of resistance factors in *EGFR* mutant lung cancer resistant to EGFR-TKIs.** Results of a joint study of Japanese patients with *EGFR*-mutant lung cancer conducted at 12 facilities to determine the clinical significance of resistance triggered by HGF.

**A.** Of 23 tumors with acquired resistance, 14 had high levels of HGF expression (61%), 12 had T790M (52%), and 2 had *Met* amplification (9%). High levels of HGF expression were detected most often. T790M and HGF are often both present in tumors that have developed acquired resistance to gefitinib and erlotinib. **B.** Of 45 tumors that did not respond to EGFR-TKI despite having *EGFR* mutations, 13 had high levels of HGF expression (29%), 0 had T790M (0%), and 4 had *Met* amplification (4%). High levels of HGF expression were again detected most often. These results suggest that HGF induces acquired and intrinsic resistance to EGFR-TKI and is the most prevalent factor for resistance

**Figure 4 Ligand-triggered resistance to EGFR inhibitors and ALK inhibitors.** **A.** In *EGFR* mutant lung cancer cells, HGF activates Met and downstream PI3K/Akt pathway and triggers resistance to EGFR-TKIs. **B.** In *EGFR* wild type lung cancer cells, HGF activates Met and downstream PI3K/Akt pathway and triggers resistance to anti-EGFR antibody, cetuximab. **C.** In *EML4-ALK* lung cancer cells, EGFR ligands activate EGFR and downstream PI3K/Akt and ERK1/2 pathways and triggers resistance to crizotinib.

**Figure 5 Strategies to treat HGF-triggered resistance.** HGF-triggered resistance can be overcome by blocking both EGFR pathway and HGF-Met pathway. EGFR signal can be blocked by reversible EGFR-TKIs, irreversible EGFR-TKIs, and mutant EGFR selective TKIs. HGF-Met signal can be blocked by neutralization of HGF, inhibition of HGF-Met binding, inhibition of Met kinase, and inhibition of downstream molecules such as PI3K and mTOR.

Table 1 Major mechanisms of EGFR-TKI resistance in *EGFR* mutant lung cancer

	Acquired resist.	Intrinsic resist.
<b>Alteration of target gene</b>		
Gatekeeper mutation (secondary mutation:T790M)	○	
<b>Activation of bypass signal</b>		
Receptor gene amplification (Met)	○	
Activation of ligand (HGF)	○	○
Receptor activation by epigenetic mechanism		
<b>Alteration of downstream</b>		
PIK3CA mutation	○	
PTEN loss	○	
BIM suppression		○
<b>Others</b>		
SCLC transformation	○	
EMT	○	

○ : involved

<b>Reversible resist.</b>	<b>Reference</b>
?	20, 21
	23
?	11
○	50
	26
	25
	27
	26
	26

Figure 1 Resistance signals to EGFR-TKIs in *EGFR* mutant lung cancer cells




Figure 2 Roles of HGF-Met in lung cancer






Figure 3 Incidence of resistance factors in *EGFR* mutant lung cancer resistant to EGFR-TKIs

A. Acquired resistance (N=23)




B. Intrinsic resistance (N=45)




**Figure 4 Ligand-triggered resistance to EGFR inhibitors and ALK inhibitors**


**A. HGF-triggered resistance to EGFR-TKIs**



**B. HGF-triggered resistance to cetuximab**



**C. EGFR ligand-triggered resistance to crizotinib**



**Figure 5 Strategies to treat HGF-triggered resistance**

